ORMP Key Stats
- Oramed to Present at Upcoming Conferences noodls 03/06 09:26 ET
- Oramed to Present Results from its Phase 2a FDA Trial with ORMD-0801 at the 2014 Diabetes Summit on April 24, 2014 noodls 03/03 09:03 ET
- Oramed Pharmaceuticals (ORMP) Mentioned Cautiously in New York Observer Street Insider 02/26 11:44 ET
- Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail! The Street 02/21 01:00 ET
- ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhi Yahoo 02/12 15:16 ET
- Oramed Submits Phase 2a Protocol to FDA for the Treatment of Type 1 Diabetes with its Oral Insulin Capsule noodls 02/10 11:05 ET
- Oramed submits Phase 2a protocol to FDA for treatment of Type 1 diabetes Yahoo 02/10 09:54 ET
- Oramed Pharma (ORMP) Submits ORMD 0801 Phase 2a Protocol Street Insider 02/10 09:49 ET
- The Dream Of The Insulin Pill: Oramed Vs. Rivals Yahoo 02/06 06:51 ET
- Analysis Of Oramed's Positive Phase IIa Safety Data Makes Opportunity Obvious Yahoo 02/05 03:20 ET
ORMP Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Oramed Pharmaceuticals is up 64.67% over the last year vs S&P 500 Total Return up 24.21%, ARCA biopharma down 14.61%, and Cormedix up 229.0%.
Balance Sheet View Statement
Pro Ratings for ORMP
Pro Strategies Featuring ORMP
Did Oramed Pharmaceuticals make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
- Sector: Healthcare
- Industry: Biotechnology
- Headquarters Country: Israel
- Headquarters State/Province: N/A
- Incorporation Country: United States
- Incorporation State/Province: Delaware
Oramed Pharmaceuticals is a pharmaceutical company. It is engaged in the research and development of innovative pharmaceutical solutions, including an orally ingestible insulin capsule or tablet.